Trust Co. of Virginia VA trimmed its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 1.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 167,937 shares of the pharmaceutical company’s stock after selling 1,625 shares during the quarter. Trust Co. of Virginia VA’s holdings in GlaxoSmithKline PLC were worth $7,242,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of GSK. Bronfman E.L. Rothschild L.P. raised its holdings in shares of GlaxoSmithKline PLC by 45.4% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after purchasing an additional 753 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in shares of GlaxoSmithKline PLC by 1,747.4% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after purchasing an additional 2,359 shares during the period. Proficio Capital Partners LLC raised its holdings in shares of GlaxoSmithKline PLC by 233.0% during the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after purchasing an additional 1,990 shares during the period. Heritage Trust Co acquired a new stake in shares of GlaxoSmithKline PLC during the first quarter worth $123,000. Finally, Westwood Holdings Group Inc. raised its holdings in shares of GlaxoSmithKline PLC by 15.7% during the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 9.28% of the company’s stock.
GlaxoSmithKline PLC (NYSE:GSK) traded down 0.25% during trading on Friday, reaching $40.05. 2,015,586 shares of the company’s stock traded hands. The company has a market capitalization of $97.88 billion, a price-to-earnings ratio of 39.58 and a beta of 1.03. The firm’s 50 day moving average is $40.01 and its 200-day moving average is $41.81. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54.
GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The business had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. Analysts expect that GlaxoSmithKline PLC will post $2.86 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a $0.491 dividend. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.90%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is currently 197.00%.
A number of analysts have weighed in on GSK shares. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 13th. BidaskClub raised shares of GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Tuesday, July 18th. Argus reaffirmed a “buy” rating and issued a $50.00 price objective on shares of GlaxoSmithKline PLC in a report on Thursday, August 31st. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and a consensus target price of $46.00.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/09/10/glaxosmithkline-plc-gsk-shares-sold-by-trust-co-of-virginia-va.html.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.